MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA
Q1 2026 Positive Adjusted EBITDA(1) Net Revenue of $9M with strong gross margins of 37% OPEX decreased 28% in Q1 2026 versus Q4 2025 Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities Management to Host Conference Call / Webcast on May 13th, […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.